COPAXONE 20 MG
GLATIRAMER ACETATE : 20 MG · DIN 02233014 · TEVA PHARMACEUTICAL INDUSTRIES LTD
Health Canada status: CANCELLED POST MARKET
What is COPAXONE?
COPAXONE 20 MG contains GLATIRAMER ACETATE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02233014, held by TEVA PHARMACEUTICAL INDUSTRIES LTD, supplied as POWDER FOR SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 28-Apr-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02233014 |
|---|---|
| Brand name | COPAXONE |
| Generic / active ingredient | GLATIRAMER ACETATE : 20 MG |
| Manufacturer | TEVA PHARMACEUTICAL INDUSTRIES LTD |
| Strength | 20 MG |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L03AX13 GLATIRAMER ACETATE |
| AHFS class | 92:20.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 28-Apr-2011 |
| Original market date | 1997-10-14 00:00:00 |
Is GLATIRAMER ACETATE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by MYLAN PHARMACEUTICALS ULC, last seen 03 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L03AX13 GLATIRAMER ACETATE. 4 of 8 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| COPAXONE | 20 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02245619 |
| COPAXONE | 40 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | DIN 02456915 |
| GLATECT | 20 MG | SOLUTION | PHARMASCIENCE INC | MARKETED | DIN 02460661 |
| GLATIRAMER ACETATE INJECTION | 20 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02541440 |
| COPAXONE | 40 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02512173 |
| TEVA-GLATIRAMER ACETATE | 20 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02441446 |
| TEVA-GLATIRAMER ACETATE | 40 MG | SOLUTION | TEVA CANADA LIMITED | APPROVED | DIN 02481510 |
Who else supplies GLATIRAMER ACETATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GLATIRAMER ACETATE appears in 40 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.